SYDNEY-BASED biotech company Immutep has announced a licensing agreement with Indian pharma company Dr Reddy's to commercialise its lead drug candidate efti (eftilagimod alfa) in all countries outside of North America, Europe, Japan and China.
Efti is a first-in-class novel immunotherapy that directly activates the immune system to fight cancer, and is currently undergoing phase III trials for the first-line therapy of advanced or metastatic non-small cell lung cancer.
Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy, radiotherapy, and/or chemotherapy.
The drug is also being investigated in other indications including head and neck cancer, breast cancer, and soft tissue sarcoma.
"This agreement with Dr Reddy's marks a significant milestone for Immutep and further validates the potential of efti," said Immutep CEO Marc Voigt.
"Dr Reddy's proven capabilities and reach in the licensed markets make them an ideal partner to maximise the impact of our innovation and serve a large number of patients across the globe," he said, adding that Immutep remains "well-positioned for future value creation".
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Dec 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Dec 25
